Ascletis Pharma Inc. has announced positive topline results from a 13-week Phase II clinical study evaluating ASC30, an oral small molecule GLP-1 receptor agonist, for the treatment of obesity or overweight with at least one weight-related comorbidity. The study, conducted at multiple sites in the United States and involving 125 participants, investigated three dose levels of ASC30 oral tablets (20 mg, 40 mg, and 60 mg). All three doses met the primary endpoint compared to placebo, demonstrating a placebo-adjusted weight loss of 7.7% and improved gastrointestinal tolerability. The results have already been presented in the company's announcement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251208-11947926), on December 08, 2025, and is solely responsible for the information contained therein.